Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amitiza

- PMLiVE

Merz, Lilly and Daiichi-Sankyo breach ABPI code

Pharma companies 'named and shamed' for inappropriate marketing in the UK

- PMLiVE

NICE backs Servier’s heart failure drug Procoralan

But recommendation includes a number of restrictions that limit NHS use of the drug

- PMLiVE

Medicines optimisation will be ‘core business’ for UK pharma

Chief pharmaceutical officer says industry will be a key partner in the agenda

- PMLiVE

J&J, Lilly and Merck join forces on clinical trials

Will set up database to improve efficiency of industry-sponsored drug trials

- PMLiVE

Lilly takes Xeljanz rival baricitinib into phase III

Its partner Incyte says baricitinib could become the number one JAK inhibitor for RA

- PMLiVE

Lilly launches diabetes partnership programme in South Africa

Partners with Project Hope and Donald Woods Foundation

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

Lilly’s Cialis cleared for BPH in Europe

Opens up a lucrative new market for the ED drug

- PMLiVE

Lilly promotes Melissa Barnes to chief ethics and compliance officer

Will replace Anne Nobles who retires at the end of 2012

- PMLiVE

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links